focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 440.00
Bid: 430.00
Ask: 450.00
Change: 0.00 (0.00%)
Spread: 20.00 (4.651%)
Open: 440.00
High: 440.00
Low: 440.00
Prev. Close: 440.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

French study shows superiority of Tristel Wipes

1 Dec 2015 11:05

RNS Number : 5512H
Tristel PLC
01 December 2015
 

 

Tristel plc

("Tristel" or "the Company")

 

French study shows superiority of Tristel Wipes System

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that a French study conducted at a leading university hospital has demonstrated the superiority of its chlorine dioxide wiping method over France's market leader, a peracetic acid soaking method. The methods are alternative ways to disinfect medical instruments used in the Ear, Nose and Throat ("ENT") department of a hospital.

 

The study was undertaken jointly by the infection prevention and ENT departments at the University Hospital, Lille. It focused on the ability of the two disinfectants (Tristel Wipes and Anios Anioxyde 1000) to kill to the requirements of European Standards: a) four different strains of bacteria, and b) a bacterial spore; and the time taken to do so.

 

The Tristel Wipe killed all four bacterial strains in 30 seconds compared to ten minutes for the French product. The Tristel Wipe killed the far more resistant bacterial spore in two minutes, whereas the French product was unable to so in ten minutes. The ability to kill microbes is the most important feature of an instrument disinfectant, but the time taken to do so is almost as important. The duration of the disinfection process is the rate limiting step for an ENT department - the slower it is the fewer the number of patients that can be seen during a clinic.

 

This latest study complements previous published research from the UK, Germany, Italy, New Zealand and Russia that substantiates the benefits of the Tristel Wipes System. During its latest financial year ending 30 June 2015, the Company sold £7.5 million of Wipes worldwide, of which £4.5 million were generated in the UK and £3 million in overseas markets. Tristel has a sales presence in all of the major European countries, but France is its least developed market, and the Company expects this study and other initiatives to accelerate its market penetration there.

 

Paul Swinney, CEO, comments: "We have developed a Wipes business in Germany worth over £1 million in sales, and significant footholds in Spain, Italy, Benelux, and also Scandinavia. Whilst we have a very capable distribution partner in France, the lack of French originated scientific support for our products has held us back in terms of sales. This study is a very positive step forward for us in the French market."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGGCUPUPAGGG
Date   Source Headline
15th Dec 20157:00 amRNSAGM Statement
2nd Dec 201511:37 amRNSIssue of Equity
1st Dec 201511:06 amRNSPosting of Annual Report & Notice of AGM
1st Dec 201511:05 amRNSFrench study shows superiority of Tristel Wipes
2nd Nov 20153:42 pmRNSIssue of Equity
22nd Oct 20154:02 pmRNSIssue of Equity
15th Oct 20159:50 amRNSIssue of Equity/Director Dealing
12th Oct 20157:00 amRNSFinal Results
5th Oct 20157:00 amRNSInvestor results briefing - Change of venue
1st Oct 20157:00 amRNSAppointment of Non-Executive Director
25th Sep 20151:52 pmRNSIssue of Equity
18th Sep 20157:00 amRNSNotice of Results
18th Aug 201510:14 amRNSIssue of Equity
17th Aug 20151:07 pmRNSDirector Share Transfer
6th Aug 201511:01 amRNSIssue of Equity
4th Aug 201511:57 amRNSDirectors dealing/grant of options
20th Jul 20154:25 pmRNSIssue of Equity
30th Jun 20154:59 pmRNSIssue of Equity
24th Jun 20154:08 pmRNSIssue of Equity
23rd Jun 20153:15 pmRNSIssue of Equity
18th Jun 20159:00 amRNSDirector Dealing/Issue of Equity
18th Jun 20157:00 amRNSSpecial Dividend and notice of results
9th Jun 20151:44 pmRNSTristel welcomes Cardiff University wipes study
3rd Jun 201512:20 pmRNSIssue of Equity
22nd May 201511:19 amRNSIssue of Equity
21st May 20157:00 amRNSTrading update
8th May 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSIssue of Equity/Director dealing
26th Feb 20157:01 amRNSInvestor Presentation
25th Feb 20157:00 amRNSHalf Yearly Report
6th Feb 20157:00 amRNSInvestor Results Presentation
28th Jan 20157:00 amRNSIssue of Equity
24th Dec 201411:27 amRNSGrant of Share Options
23rd Dec 20142:38 pmRNSDirector/PDMR Shareholding
16th Dec 201411:53 amRNSResult of AGM
16th Dec 20147:00 amRNSAGM Statement
21st Nov 20147:00 amRNSPosting of Annual Report & Notice of AGM
17th Nov 20143:27 pmRNSIssue of Equity
11th Nov 20147:00 amRNSNZ ENT study shows Tristel Wipes System benefits
3rd Nov 20146:02 pmRNSDirector's Shareholding
20th Oct 201411:56 amRNSIssue of Equity
13th Oct 20147:00 amRNSFinal Results
29th Sep 20147:00 amRNSInvestor Results Presentation
19th Aug 20147:00 amRNSMarket leadership in UK ENT market
28th Jul 20147:00 amRNSPre-close trading update
7th Jul 201410:03 amRNSIssue of Equity
23rd Jun 20148:30 amRNSIssue of Equity
18th Jun 201411:16 amRNSHolding(s) in Company
10th Jun 20147:00 amRNSTrading Update
22nd May 201412:37 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.